Real-World Experience of Concomitant Isavuconazole and Vincristine Administration

Clicks: 1
ID: 339428
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #150 of 150 articles by views in journal of the pediatric infectious diseases society

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 150 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Three pediatric oncology patients received isavuconazole concurrently with vincristine across 15 days to approximately 23 months, spanning 32 vincristine doses. No severe adverse effect including neurotoxicity or paralytic ileus was attributed to the combination.
Reference Key
openalex_W7225753645 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Mohamad Shieb, Theresa Madigan, James T. Gaensbauer, Abbie L. Blunier, John Guggenburger, Ashley Walter, Alexis K. Kuhn, Catherine Martin, Paul J. Galardy, Mira A. Kohorst, Anand Srinivasan, Madeleine B. O'Keefe, Laura Dinnes
Are you one of these authors? Claim your profile
Journal journal of the pediatric infectious diseases society
Year 2026
DOI
10.1093/jpids/piag116
URL
https://doi.org/10.1093/jpids/piag116
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.